鹿得医疗(832278) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for the reporting period reached ¥344,912,244.95, representing a year-on-year increase of 4.75%[4] - Net profit attributable to shareholders decreased by 12.86% to ¥27,613,023.92 compared to the previous year[4] - Basic earnings per share fell by 11.11% to ¥0.16[4] - The decline in net profit was primarily due to decreased gross margins on certain products and increased credit impairment losses[5] - The weighted average return on equity (ROE) decreased to 7.00% (before deducting non-recurring gains and losses) from 8.19%[3] Assets and Equity - Total assets at the end of the reporting period amounted to ¥529,650,132.21, reflecting a growth of 7.94% year-on-year[4] - Shareholders' equity attributable to the company increased by 2.61% to ¥399,833,341.77[4] Market and Sales - The company actively participated in various domestic and international industry exhibitions, contributing to the growth in overseas sales[5] - The company reported an increase in accounts receivable due to international geopolitical conflicts, impacting financial performance[5] Reporting and Auditing - The final financial data will be confirmed in the 2024 annual report, as the current figures are preliminary and unaudited[6]